Anixa Biosciences' CAR-T Therapy for Ovarian Cancer Presented at Ovarcome Conference.

Anixa Biosciences announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, will present at the 13th Annual Ovarcoming Cancer Conference. Dr. Wenham is the principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial. The presentation is scheduled for September 18, 2025, and will discuss advancements in ovarian cancer research and therapies, including Anixa's CAR-T therapy.

San Jose, Calif. -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, has announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center and principal investigator for the company's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will present at the 13th Annual Ovarcoming Cancer Conference. The conference will take place on September 18-19, 2025, both virtually and in-person at the Briar Club in Houston, Texas.

Dr. Wenham's presentation, scheduled for Thursday, September 18, 2025, from 12:05 PM – 12:30 PM CT, will highlight advancements in ovarian cancer research and therapies, including Anixa's CAR-T therapy. The Ovarcoming Cancer Conference brings together survivors, caregivers, and medical professionals to learn from world-renowned experts on topics of greatest importance in the ovarian cancer landscape.

Anixa Biosciences is developing an ovarian cancer immunotherapy program in collaboration with Moffitt Cancer Center, using a novel type of CAR-T known as chimeric endocrine receptor-T cell (CER-T) technology. This technology differentiates itself by using the natural ligand of the FSHR receptor, FSH, to bind to the FSHR receptor on the tumor cell, rather than an antibody fragment [1].

The company's vaccine portfolio also includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer.

Anixa's business model involves partnering with world-renowned research institutions on all stages of development to continually examine emerging technologies in complementary fields for further development and commercialization. For more information about the conference and Anixa Biosciences, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook, and YouTube.

References:
[1] https://www.marketscreener.com/news/anixa-biosciences-announces-dr-robert-wenham-will-speak-about-immunotherapy-in-surviving-ovarian-ca-ce7c5edddb8dff25
[2] https://www.anixa.com/
[3] https://www.morningstar.com/news/pr-newswire/20250808la47150/anixa-biosciences-announces-dr-robert-wenham-will-speak-about-immunotherapy-in-surviving-ovarian-cancer-at-the-13th-annual-ovarcoming-cancer-conference